Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
06/13/2013 | WO2013043032A3 Dialysed extract of leucocytes from shark spleen, for obtaining a transfer factor with increased potential, specifically designed to be used as an immunomodulator, and method for extracting, checking and counting same |
06/13/2013 | WO2013041692A3 Method to predict the presence of inflammation or itaconic acid, irg1 and/or protein irg1 in a subject and pharmaceutical composition for treating or preventing inflammation |
06/13/2013 | WO2013032248A3 Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient |
06/13/2013 | WO2013025064A3 Anti-cancer composition comprising wnt decoy receptors |
06/13/2013 | WO2013018097A3 Novel sequences for the control of reproduction in fish |
06/13/2013 | WO2013015668A3 Use of the peptide gk-1 expressed in the filamentous phage m13 for preparing pharmaceutical products that increase the effectiveness of the immune response induced by vaccine antigens or pathogens |
06/13/2013 | WO2013009910A3 Eosinophil peroxidase compositions and methods of their use |
06/13/2013 | WO2012162565A3 Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
06/13/2013 | WO2011163650A3 Methods and compositions for cns delivery of arylsulfatase a |
06/13/2013 | WO2011133960A9 Lysosomal storage disease enzyme |
06/13/2013 | US20130150649 Sensitization of tumor cells to radiation therapy through administration of endothelin agonists |
06/13/2013 | US20130150555 Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock |
06/13/2013 | US20130150432 Efficacy of cancer therapy |
06/13/2013 | US20130150311 Mixed poloxamer excipients |
06/13/2013 | US20130150310 Compositions and Methods for Treatment of Cancer |
06/13/2013 | US20130150309 Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction |
06/13/2013 | US20130150307 Injection paradigm for administration of botulinum toxins |
06/13/2013 | US20130150306 Milk-based nutritional compositions containing lactoferrin and uses thereof |
06/13/2013 | US20130150304 Treatment of a disease associated with retinal degenerative disorder |
06/13/2013 | US20130150302 Conjugated blood coagulation factor viii |
06/13/2013 | US20130150301 Therapeutic agents for regulating serum phosphorus |
06/13/2013 | US20130150299 Template-fixed peptidomimetics |
06/13/2013 | US20130150298 Parstatin peptides |
06/13/2013 | US20130150296 Albumin fusion proteins |
06/13/2013 | US20130150295 Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents |
06/13/2013 | US20130150293 Method for preventing and treating diabetes using neurturin |
06/13/2013 | US20130150292 Soft Protease Inhibitors and Pro-Soft Forms Thereof |
06/13/2013 | US20130150288 Treatment of viral infections |
06/13/2013 | US20130150286 Methods and pharmaceutical compositions for the treatment of respiratory tract infections |
06/13/2013 | US20130150285 Therapeutic and cosmetic uses and applications of calreticulin |
06/13/2013 | US20130150284 Immobilized biologically active entities having a high degree of biological activity |
06/13/2013 | US20130149744 Methods for Producing a Fusion Protein Capable of Binding VEGF |
06/13/2013 | US20130149719 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents |
06/13/2013 | US20130149356 Muscle-based grafts/implants |
06/13/2013 | US20130149343 Hemostatic Bioabsorbable Device with Polyethylene Glycol Binder |
06/13/2013 | US20130149334 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
06/13/2013 | US20130149321 Candidates against infection |
06/13/2013 | US20130149320 Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer |
06/13/2013 | US20130149314 p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth |
06/13/2013 | US20130149311 Gfi1b modulation and uses thereof |
06/13/2013 | US20130149307 Humanized anti-egfl7 antibodies and methods using same |
06/13/2013 | US20130149306 Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents |
06/13/2013 | US20130149299 Dosages for treatment with anti-egfr antibodies |
06/13/2013 | US20130149295 Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease |
06/13/2013 | US20130149294 Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
06/13/2013 | US20130149293 Stable compositions of factor ix |
06/13/2013 | US20130149292 Thrombin-free biological adhesive and use thereof as a medicament |
06/13/2013 | US20130149285 Adipose tissue-derived stem cells for veterinary use |
06/13/2013 | US20130149281 Organic compounds and their uses |
06/13/2013 | US20130149280 Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation |
06/13/2013 | DE102011122236A1 Composition useful e.g. in topical treatment of inflammatory diseases of skin and/or mucous membrane, comprises fusafungine and its derivate, and acidic glycosaminoglycan or its derivatives |
06/13/2013 | CA2858550A1 Aromatic-cationic peptides and uses of same |
06/13/2013 | CA2858379A1 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants |
06/13/2013 | CA2858148A1 Methods and products for transfecting cells |
06/13/2013 | CA2857982A1 Robust controlled-release peptide formulations |
06/13/2013 | CA2857686A1 Use of growth hormone fragments |
06/13/2013 | CA2857250A1 Compositions for preventing or treating adverse reactions of egfr inhibition |
06/13/2013 | CA2855122A1 Modified mini-hepcidin peptides and methods of using thereof |
06/13/2013 | CA2852365A1 New proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus |
06/13/2013 | CA2762338A1 Therapy for subarachnoid hemorrhage and ischemia |
06/12/2013 | EP2601966A1 Treatment of neurological or neurodegenerative disorders |
06/12/2013 | EP2601965A1 Compositions for preventing or treating adverse reactions of EGFR inhibition |
06/12/2013 | EP2601964A1 Balanol compounds for use in treating pain |
06/12/2013 | EP2601963A1 N-isovaleroyl-l-glutamyl-l-tryptophan as an agent inhibiting the formation of ulcers in the stomach and the duodenum |
06/12/2013 | EP2601962A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
06/12/2013 | EP2601961A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
06/12/2013 | EP2601934A1 Vesicular phospholipid gels comprising proteinaceous substances |
06/12/2013 | EP2601932A1 Lyophilized recombinant VWF formulations |
06/12/2013 | EP2601530A2 Compositions and methods for detecting, diagnosing, and treating cancer |
06/12/2013 | EP2601210A1 Improved recombinant human follicle-stimulating hormone |
06/12/2013 | EP2600901A2 Engineered nucleic acids and methods of use thereof |
06/12/2013 | EP2600896A2 Treating breast cancer with anti-il-19 antibody |
06/12/2013 | EP2600888A2 Novel compounds as dpp-iv inhibitors and process for preparation thereof |
06/12/2013 | EP2600887A2 Microcrystalline y receptor agonists |
06/12/2013 | EP2600886A1 Use of a peptide enhancing the ability of radiation therapy to kill cancer cells |
06/12/2013 | EP2600885A2 Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases |
06/12/2013 | EP2600884A2 Polypeptides for treating and/or limiting influenza infection |
06/12/2013 | EP2600883A1 Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof |
06/12/2013 | EP2600882A1 Antibodies against 6-sulfo-lacnac-positive human dendritic cells, and their use |
06/12/2013 | EP2600855A2 Combination therapy for the treatment of prostate carcinoma |
06/12/2013 | EP2600843A2 Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
06/12/2013 | CN1942588B Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
06/12/2013 | CN1922332B Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
06/12/2013 | CN1812804B Selective r-cadherin antagonist and methods |
06/12/2013 | CN1529753B Disease-associated protein |
06/12/2013 | CN1461310B ANtibodies that bind human interleukin-18 and methods of making and using |
06/12/2013 | CN103154024A Novel N-terminally modified insulin derivatives |
06/12/2013 | CN103153344A Methods, compositions, and kits for the treatment of matrix mineralization disorders |
06/12/2013 | CN103153340A Treatment for neoplastic diseases |
06/12/2013 | CN103153337A Mucosal adjuvant composition |
06/12/2013 | CN103153335A Small-molecule-targeted protein degradation |
06/12/2013 | CN103153334A New emd formulation comprising pga |
06/12/2013 | CN103153333A Method for purification of complement factor H |
06/12/2013 | CN103153332A Compositions and methods for treatment of hematological malignancies |
06/12/2013 | CN103153331A Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods |
06/12/2013 | CN103153330A Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
06/12/2013 | CN103153329A Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
06/12/2013 | CN103153328A Peptide for use in the treatment of breast cancer and/or bone metastases |
06/12/2013 | CN103153327A Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
06/12/2013 | CN103153326A Peptides containing tryptophan |